Skip to main content
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc. — Investor Relations & Filings

Ticker · COYA ISIN · US22407B1089 US Manufacturing
Filings indexed 206 across all filing types
Latest filing 2025-02-26 Director's Dealing
Country US United States of America
Listing US COYA

About Coya Therapeutics, Inc.

https://www.coyatherapeutics.com/

Coya Therapeutics, Inc. is a clinical-stage biotechnology company that develops proprietary biologics and multi-modality therapies designed to enhance the function of regulatory T cells (Tregs). The company's approach focuses on modulating dysfunctional Tregs to suppress inflammation associated with neurodegenerative, autoimmune, and metabolic diseases. Its lead product candidate, COYA 302, is an investigational biologic combination therapy being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS). The pipeline also includes other candidates such as COYA 303, a combination of low-dose Interleukin-2 (IL-2) and a GLP-1 receptor agonist, intended for inflammation-driven diseases.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-02-26 English
4
Director's Dealing
2025-02-26 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-10 English
S-8
Registration Form
2025-01-30 English
4
Director's Dealing
2025-01-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.